# A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease

> **NCT06346288** · PHASE4 · COMPLETED · sponsor: **AbbVie** · enrollment: 10 (actual)

## Conditions studied

- Inflammatory Bowel Disease

## Interventions

- **PROCEDURE:** Breast Milk Sampling
- **DRUG:** Risankizumab

## Key facts

- **NCT ID:** NCT06346288
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-24
- **Primary completion:** 2026-02-05
- **Final completion:** 2026-02-05
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06346288

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06346288, "A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06346288. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*